Objective:High-grade (WHO grade III and IV) gliomas account for approximately 70% of all gliomas, and glioblastomas (GBM) account for more than 50% of gliomas. In the past, the median survival of GBM rarely exceeded 1 year, and the median survival of mesenchymal astrocytoma (AA) was only 12-24 months, but a very small number of cases survived for a longer period (>6 years) after treatment. METHODS: By retrospectively summarizing (searching medical records) and following up (patient follow-up, telephone and letter contact) the patients with glioma treated by our department in the past 15 years (2000-2014), we found some unimaginably long (more than 10 years) and high quality survival cases, and we summarize and report 10 cases with more complete data. Among them, there was one case of glioblastoma, one case of mesenchymal astrocytoma, two cases of mesenchymal oligodendrocytoma, three cases of mesenchymal oligodendrocytoma, and three cases of astrocytoma grade 2. The longest survivor among these ten cases was more than 20 years, and most of the patients were still able to live and work normally. Results:These cases have the following characteristics: 1. All of them have undergone aggressive standardized surgery and must have undergone maximum safe resection of the tumor, with some radical enlargement, and the same for those who can operate after recurrence; 2. Most of them have undergone (10/12) adequate radiotherapy, among which 3 cases were treated with X-knife or Gamma knife for recurrence due to irregular or insufficient dose of the first radiotherapy; 3. 6 cases underwent chemotherapy with ACNU (Nintelang), 2 cases had later chemotherapy with temozolomide, and 2 cases did not undergo chemotherapy; 4. Tumor sites: 3 cases in the frontal lobe, 3 cases in the temporal lobe, 3 cases in the cerebellum, and 1 case in the pineal region; 5. Relatively young age (all were less than 50 years old at the time of onset); 6. Patients and their families had an urgent desire for treatment, a strong desire to live, and good family economic situation. Conclusion:Although the overall prognosis of glioma patients is still poor, there are indeed a few cases that can survive with high quality for a long time with active treatment. We think that for younger patients, especially when the tumor is located in the prefrontal lobe, anterior temporal lobe and unilateral cerebellar area, we should firstly adopt a more radical surgery (lobectomy), followed by individualized and comprehensive treatment such as radiotherapy and chemotherapy as much as possible, establish strong confidence and strong desire for survival, and insist on active treatment, which may indeed bring patients with glioma a better chance of long-term survival and better prognosis.